Disclaimer: We may earn a commission if you make any purchase by clicking our links. Please see our detailed guide here.

Follow us on:

GSK-CureVac’s 2nd Covid Vax Shows Better Immune Response

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.

Join the Opinion Leaders Network

Join the Techgenyz Opinion Leaders Network today and become part of a vibrant community of change-makers. Together, we can create a brighter future by shaping opinions, driving conversations, and transforming ideas into reality.

The second mRNA Covid-19 Vaccine developed by German biopharmaceutical company CureVac, and its British partner GlaxoSmithKline (GSK) has demonstrated improved immune response and protection than its first vaccine, according to a new study.

The animal-based study, yet to be peer-reviewed and posted on pre-print server bioRxiv, shows that CV2CoV has a higher neutralizing capacity against a range of variants, including the Beta, Delta, and Lambda variants and the original virus strain, the company said in a statement on Monday.

CureVac’s first mRNA-based Covid vaccine CVnCoV showed the efficacy of just 47 percent, the lowest reported so far from any Covid-19 vaccine maker.

The new study assessed cynomolgus macaques vaccinated with 12 micrograms of either the first or second-generation vaccine candidate.

Improved activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation compared to the first-generation candidate, CVnCoV.

The company said that when tested against the original SARS-CoV-2 virus, the animals vaccinated with CV2CoV were better protected based on highly effective clearance of the virus in the lungs and nasal passages.

“In this animal model, CV2CoV is shown to induce broad antibody and cellular immune responses very similar to the breadth of the immune responses observed after infection with SARS-CoV-2,” said Dr. Igor Splawski Chief Scientific Officer of CureVac.

The companies aim to roll out CV2CoV’s Phase 1 clinical trial in Q4 2021.

The mRNA technology was a “strategic priority”, said Rino Rappuoli, head of vaccines research and development at GSK

“The strong immune response and protection in pre-clinical testing of this second-generation mRNA backbone are very encouraging and represent an important milestone,” he added.

Meanwhile, CureVac faced heavy losses in the second quarter. Its operating loss was 147.8m euros for the three months ending June 30, compared with a loss of 3.2m euros in the second quarter of 2020.

Revenue was 22.4m euros, down 35 percent from a year ago.

Partner With Us

Digital advertising offers a way for your business to reach out and make much-needed connections with your audience in a meaningful way. Advertising on Techgenyz will help you build brand awareness, increase website traffic, generate qualified leads, and grow your business.

Join 10,000+ Fellow Readers

Get Techgenyz’s roundup delivered to your inbox curated with the most important for you that keeps you updated about the future tech, mobile, space, gaming, business and more.


Find Apps

The Ultimate Hub for Discovering Apps Unlock a world of apps: your ultimate hub for exploring and discovering limitless possibilities for on your every needs.

Power Your Business

Solutions you need to super charge your business and drive growth

More from this topic